Gary D. Novack
About
In The Last Decade
Gary D. Novack
176 papers receiving 4.2k citations
Hit Papers
Peers
Comparison fields: 5 of 130
- Ophthalmology 3.0k
- Public Health, Environmental and Occupational Health 1.7k
- Radiology, Nuclear Medicine and Imaging 1.4k
- Molecular Biology 637
- Immunology and Allergy 324
Countries citing papers authored by Gary D. Novack
This map shows the geographic impact of Gary D. Novack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary D. Novack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary D. Novack more than expected).
Fields of papers citing papers by Gary D. Novack
This network shows the impact of papers produced by Gary D. Novack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary D. Novack. The network helps show where Gary D. Novack may publish in the future.
Co-authorship network of co-authors of Gary D. Novack
This figure shows the co-authorship network connecting the top 25 collaborators of Gary D. Novack. A scholar is included among the top collaborators of Gary D. Novack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary D. Novack. Gary D. Novack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 3 | |
| 4 | 1 | |
| 5 | 1 | |
| 6 | 4 | |
| 7 | Long-term Safety and Ocular Hypotensive Efficacy of Netarsudil Ophthalmic Solution: The ROCKET-2 Study | 1 |
| 8 | The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in Humans | 2 |
| 9 | TFOS DEWS II Report Executive Summary breakdown → | 583 |
| 10 | 5 | |
| 11 | Evaluation of AR-13324, a novel dual mechanism agent, in lowering of IOP in glaucoma and ocular hypertension | 8 |
| 12 | Ocular hypotensive efficacy and safety of a fixed dose combination of AR-12286 (a Rho Kinase Inhibitor) and travoprost | 2 |
| 13 | Ocular Hypotensive Efficacy and Safety of the Rho Kinase Inhibitor AR-12286 in Patients With Elevated Intraocular Pressure | 2 |
| 14 | A Comparison of Adherence to Glaucoma Medical Therapy for Patients on One Medication Compared to Two Different Medications Using a Computerized Medications Event Monitoring System (MEMS) Device | 1 |
| 15 | Pirenzepine 2% Ophthalmic Gel retards myopic progression in 8–12 year old children over two years | 8 |
| 16 | Electronic Monitoring System to Assess Patient Adherence in Pediatric Drug Studies | 2 |
| 17 | Comparative efficacy of loteprednol etabonate and prednisolone acetate in the conjunctival provocation test model of ocular allergy | 1 |
| 18 | 18 | |
| 19 | 6 | |
| 20 | EEG and behavioral effects of morphine in dogs. | 4 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.